Lifecore Q2 FY25 revenue up 8% to $32.6M; net loss $6.6M on non-cash items; adj EBITDA $6.5M

LIFECORE BIOMEDICAL, INC. DE

2025-FY EPS reported -$1.06 revenue$62,956,000

Revenue $32.6M (+8% YoY); CDMO segment drove $1.9M increase, partially offset by customer mix shifts.
Net loss of $6.6M ($0.25 diluted loss) vs prior-year net income of $14.2M which included a $20.7M non-cash gain.
Adjusted EBITDA $6.5M, up from $5.4M YoY, driven by higher gross profit from pricing and mix.
Completed $24.3M equity private placement and amended BMO credit facility with lower rates and 3-year extension.
Signed new CDMO project with Nirsum Labs; installed GMP-ready 5-head isolator filler, doubling capacity to ~$300M annual revenue potential.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.